Zobrazeno 1 - 10
of 279
pro vyhledávání: '"Elisabetta, Marangoni"'
Autor:
Ozge Saatci, Metin Cetin, Meral Uner, Unal Metin Tokat, Ioulia Chatzistamou, Pelin Gulizar Ersan, Elodie Montaudon, Aytekin Akyol, Sercan Aksoy, Aysegul Uner, Elisabetta Marangoni, Mathew Sajish, Ozgur Sahin
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-20 (2023)
Abstract Resistance to endocrine therapy and CDK4/6 inhibitors, the standard of care (SOC) in estrogen receptor-positive (ER+) breast cancer, greatly reduces patient survival. Therefore, elucidating the mechanisms of sensitivity and resistance to SOC
Externí odkaz:
https://doaj.org/article/12ad9995bcd94038ac3e1cc764cb8625
Autor:
Rania El‐Botty, Sophie Vacher, Juliette Mainguené, Adrien Briaux, Sabrina Ibadioune, Ahmed Dahmani, Elodie Montaudon, Fariba Nemati, Léa Huguet, Laura Sourd, Ludivine Morriset, Sophie Château‐Joubert, Thierry Dubois, Virginie Maire, Rosette Lidereau, Audrey Rapinat, David Gentien, Florence Coussy, Ivan Bièche, Elisabetta Marangoni
Publikováno v:
Molecular Oncology, Vol 17, Iss 10, Pp 2017-2028 (2023)
Triple negative breast cancers (TNBCs) represent 15–20% of all breast cancers and are associated with higher recurrence and distant metastasis rate. Standard of care for early stage TNBC is anthracyclines combined with cyclophosphamide (AC) followe
Externí odkaz:
https://doaj.org/article/544d9d964bc94114b651429060007609
Autor:
Mads Haugland Haugen, Hedda von der Lippe Gythfeldt, Eivind Valen Egeland, Lisa Svartdal Normann, Abhilash D. Pandya, Lise‐Lotte Vedin, Siri Juell, Ellen Tenstad, Geir Frode Øy, Alexandr Kristian, Elisabetta Marangoni, Therese Sørlie, Knut Steffensen, Gunhild Mari Mælandsmo, Olav Engebraaten
Publikováno v:
Molecular Oncology, Vol 17, Iss 10, Pp 2041-2055 (2023)
Liver X receptors (LXRs) are nuclear transcription factors important in the regulation of cholesterol transport, and glucose and fatty acid metabolism. The antiproliferative role of LXRs has been studied in a variety of malignancies and may represent
Externí odkaz:
https://doaj.org/article/f082ee37ad4f4724ba7aa48e46c2a756
Autor:
Coralie Poulard, Thuy Ha Pham, Youenn Drouet, Julien Jacquemetton, Ausra Surmielova, Loay Kassem, Benoite Mery, Christine Lasset, Jonathan Reboulet, Isabelle Treilleux, Elisabetta Marangoni, Olivier Trédan, Muriel Le Romancer
Publikováno v:
EMBO Molecular Medicine, Vol 15, Iss 8, Pp 1-20 (2023)
Abstract Endocrine therapies targeting estrogen signaling, such as tamoxifen, have significantly improved management of estrogen receptor alpha (ERα)‐positive breast cancers. However, their efficacy is limited by intrinsic and acquired resistance
Externí odkaz:
https://doaj.org/article/26bc168fc37e4a74ac05932309583845
Autor:
Rania El-Botty, Ludivine Morriset, Elodie Montaudon, Zakia Tariq, Anne Schnitzler, Marina Bacci, Nicla Lorito, Laura Sourd, Léa Huguet, Ahmed Dahmani, Pierre Painsec, Heloise Derrien, Sophie Vacher, Julien Masliah-Planchon, Virginie Raynal, Sylvain Baulande, Thibaut Larcher, Anne Vincent-Salomon, Guillaume Dutertre, Paul Cottu, Géraldine Gentric, Fatima Mechta-Grigoriou, Scott Hutton, Keltouma Driouch, Ivan Bièche, Andrea Morandi, Elisabetta Marangoni
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-16 (2023)
Abstract Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability in most patients with estrogen receptor positive breast cancers (ER + BC). By genomic and metabolomics analyses of patients’ tumours, metastasis-de
Externí odkaz:
https://doaj.org/article/b26393ab46f442b18957dda9286c9e24
Autor:
Petra ter Brugge, Sarah C. Moser, Ivan Bièche, Petra Kristel, Sabrina Ibadioune, Alexandre Eeckhoutte, Roebi de Bruijn, Eline van der Burg, Catrin Lutz, Stefano Annunziato, Julian de Ruiter, Julien Masliah Planchon, Sophie Vacher, Laura Courtois, Rania El-Botty, Ahmed Dahmani, Elodie Montaudon, Ludivine Morisset, Laura Sourd, Léa Huguet, Heloise Derrien, Fariba Nemati, Sophie Chateau-Joubert, Thibaut Larcher, Anne Salomon, Didier Decaudin, Fabien Reyal, Florence Coussy, Tatiana Popova, Jelle Wesseling, Marc-Henri Stern, Jos Jonkers, Elisabetta Marangoni
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Homologous recombination deficiency is linked with platinum-based chemotherapy response in triple-negative breast cancer (TNBC) but methods to clinically identify these patients are lacking. Here, using patient-derived xenografts of TNBC the authors
Externí odkaz:
https://doaj.org/article/45c67b1c1e0a4a2998d04e87b0b265a7
Autor:
Ian S. Miller, Sonja Khan, Liam P. Shiels, Sudipto Das, Alice C. O' Farrell, Kate Connor, Adam Lafferty, Bruce Moran, Claudio Isella, Paul Loadman, Emer Conroy, Susan Cohrs, Roger Schibli, Robert S. Kerbel, William M. Gallagher, Elisabetta Marangoni, Kathleen Bennett, Darran P. O' Connor, Róisín M. Dwyer, Annette T. Byrne
Publikováno v:
Cancer Medicine, Vol 11, Iss 20, Pp 3820-3836 (2022)
Abstract Backgorund Prior data suggest pre‐diagnostic aspirin use impacts breast tumour biology and patient outcome. Here, we employed faithful surgical resection models of HER2+ and triple‐negative breast cancer (TNBC), to study outcome and resp
Externí odkaz:
https://doaj.org/article/1f5177ae512441ffab056e955c214925
Autor:
Gaia Bianco, Mairene Coto-Llerena, John Gallon, Venkatesh Kancherla, Stephanie Taha-Mehlitz, Mattia Marinucci, Martina Konantz, Sumana Srivatsa, Hesam Montazeri, Federica Panebianco, Vijaya G. Tirunagaru, Marta De Menna, Viola Paradiso, Caner Ercan, Ahmed Dahmani, Elodie Montaudon, Niko Beerenwinkel, Marianna Kruithof-de Julio, Luigi M. Terracciano, Claudia Lengerke, Rinath M. Jeselsohn, Robert C. Doebele, François-Clément Bidard, Elisabetta Marangoni, Charlotte K. Y. Ng, Salvatore Piscuoglio
Publikováno v:
Communications Biology, Vol 5, Iss 1, Pp 1-15 (2022)
GATA3 mutations are common in ER-positive breast cancers yet are not targetable. This study describes pharmacological inhibition of MDM2 as a novel approach to target GATA3 deficiency, providing a molecularly guided treatment for this patient subclas
Externí odkaz:
https://doaj.org/article/9071cb3253ff484fad39debd9d0d2d7d
Autor:
Guus J. J. E. Heynen, Kamil Lisek, Regina Vogel, Annika Wulf-Goldenberg, Joshua Alcaniz, Elodie Montaudon, Elisabetta Marangoni, Walter Birchmeier
Publikováno v:
Breast Cancer Research, Vol 24, Iss 1, Pp 1-15 (2022)
Abstract Background PI3K signaling is frequently activated in breast cancer and is targeted by PI3K inhibitors. However, resistance of tumor cells to PI3K inhibition, often mediated by activated receptor tyrosine kinases, is commonly observed and red
Externí odkaz:
https://doaj.org/article/c69ce1776048465cb6d9ef9dd5f6f21e
Autor:
Varduhi Petrosyan, Lacey E. Dobrolecki, Lillian Thistlethwaite, Alaina N. Lewis, Christina Sallas, Ramakrishnan R. Srinivasan, Jonathan T. Lei, Vladimir Kovacevic, Predrag Obradovic, Matthew J. Ellis, C. Kent Osborne, Mothaffar F. Rimawi, Anne Pavlick, Maryam Nemati Shafaee, Heidi Dowst, Antrix Jain, Alexander B. Saltzman, Anna Malovannaya, Elisabetta Marangoni, Alana L. Welm, Bryan E. Welm, Shunqiang Li, Gerburg M. Wulf, Olmo Sonzogni, Chen Huang, Suhas Vasaikar, Susan G. Hilsenbeck, Bing Zhang, Aleksandar Milosavljevic, Michael T. Lewis
Publikováno v:
iScience, Vol 26, Iss 1, Pp 105799- (2023)
Summary: Although systemic chemotherapy remains the standard of care for TNBC, even combination chemotherapy is often ineffective. The identification of biomarkers for differential chemotherapy response would allow for the selection of responsive pat
Externí odkaz:
https://doaj.org/article/2b0f86504c374089a6c4e5c09a09e1cb